Last news
Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale

Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale

New platform reinforces Infobip's shift to AI-first customer experience in its 20th year KUALA LUMPUR, Malaysia, March 2, 2026 /PRNewswire/ -- Global AI-first cloud communications platform Infobip, which celebrates its 20th anniversary this year, is...

SK Telecom CEO Unveils 'AI Native' Strategy at MWC26, Driving Korea's Leap in AI Innovation

SK Telecom CEO Unveils 'AI Native' Strategy at MWC26, Driving Korea's Leap in AI Innovation

- Seizing the golden time for a major transformation, with 'Customer Value & AI' as the top two priorities for driving change - Major overhaul of systems and infrastructure, the foundation of telecommunications, centered on AI - Redesigning...

XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three...

Firmable Raises $14m Series A to Take AI-Native Sales Platform Global

Firmable Raises $14m Series A to Take AI-Native Sales Platform Global

MELBOURNE, Australia, March 2, 2026 /PRNewswire/ -- Firmable, Asia-Pacific's leading AI (artificial intelligence) sales platform, has raised $14 million in Series A funding led by Airtree, with participation from existing investors. The funding will...

Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis

Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis

SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today...

Toku Reports US$34.8 million Revenue in FY2025 as AI Adoption Gains Traction; Underlying Loss Improves

Toku Reports US$34.8 million Revenue in FY2025 as AI Adoption Gains Traction; Underlying Loss Improves

SINGAPORE, March 2, 2026 /PRNewswire/ -- Toku Ltd. ("Toku", "投酷有限公司" or the "Company", and together with its subsidiaries, the "Group"), a Singapore-incorporated AI-powered customer experience (CX) platform, is pleased to announce its financial...

Understanding China's whole-process people's democracy

Understanding China's whole-process people's democracy

BEIJING, March 2, 2026 /PRNewswire/ -- A report from People's Daily: The upcoming "two sessions," the annual meetings of China's top legislature, the National People's Congress (NPC), and the top political advisory body, the National Committee of...

Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

SAN FRANCISCO and SUZHOU, China, March 2, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...

1 ... 16 17 18 19 20 21 22 23 24 ... 3852
menu
menu